Abstract | BACKGROUND: METHODS: RESULTS: We demonstrated that the product of the platelet-to-lymphocyte ratio (PLR) multiplied by the cytokeratin-19 fragment (CYFRA) level, which was termed "PLR-CYFRA," is the most accurate indicator that predicts the pathological response to neoadjuvant chemotherapy, with the highest area under the curve [0.795 (95% confidence interval: 0.665-0.925), P < 0.001] in receiver operating characteristic analyses. Therefore, we divided patients into the PLR-CYFRALow (< 237.6, n = 21) and PLR-CYFRAHigh (≥ 237.6, n = 45) groups and found that the percentage of PLR-CYFRALow was significantly higher in patients with a better pathological response (P < 0.001). Furthermore, patients with good pathological response had significantly better prognoses in terms of disease-specific survival (P = 0.014), recurrence-free survival (P = 0.014), and overall survival (P = 0.032). In the multivariate analysis, PLR-CYFRA was an independent predictor of the pathological response of patients with esophageal squamous cell carcinoma to neoadjuvant chemotherapy (P = 0.002). CONCLUSION:
|
Authors | Yuji Shishido, Tomoyuki Matsunaga, Shohei Sawata, Masahiro Makinoya, Wataru Miyauchi, Kozo Miyatani, Chihiro Uejima, Masaki Morimoto, Yuki Murakami, Takehiko Hanaki, Kyoichi Kihara, Manabu Yamamoto, Naruo Tokuyasu, Shuichi Takano, Teruhisa Sakamoto, Hiroaki Saito, Toshimichi Hasegawa, Yoshiyuki Fujiwara |
Journal | Yonago acta medica
(Yonago Acta Med)
Vol. 64
Issue 3
Pg. 249-259
(Aug 2021)
ISSN: 0513-5710 [Print] Japan |
PMID | 34434065
(Publication Type: Journal Article)
|
Copyright | ©2021 Tottori University Medical Press. |